Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of next-generation vaccines designed to prevent infectious diseases globally. Founded in 2017 and headquartered in San Carlos, California, Vaxcyte leverages its proprietary vaccine design platform, which incorporates genomic and immunological data to identify novel antigens and optimize immunogenicity. The company’s approach integrates advanced bioinformatics, protein engineering and cutting-edge manufacturing techniques to advance vaccine candidates from concept to clinic more efficiently than traditional methods.
The company’s lead programs include VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) designed to address remaining gaps in current pneumococcal disease protection, and VAX-A1, a peptide-based vaccine targeting Streptococcus pyogenes infections, which are responsible for a broad spectrum of illnesses ranging from pharyngitis to invasive disease. Both candidates have entered clinical trials, positioning Vaxcyte to expand upon the commercial successes of existing vaccines by offering broader coverage and enhanced immunological profiles. In parallel, Vaxcyte is advancing additional preclinical programs against other high-unmet-need pathogens using the same platform technology.
Vaxcyte’s leadership team is composed of vaccine development veterans with extensive experience in global regulatory affairs, clinical development and commercial strategy. John Maki, the company’s president and chief executive officer, brings more than two decades of industry expertise from roles at Janssen Vaccines and other biotech firms. The company’s board of directors and scientific advisory board feature experts in microbiology, immunology and public health, guiding the strategic direction and ensuring rigorous scientific standards across all programs.
While headquartered in the United States, Vaxcyte conducts multinational clinical trials and collaborates with contract manufacturing organizations to support global supply chain needs. The company’s strategic partnerships aim to accelerate late-stage development and prepare for broad distribution upon regulatory approval. Through its innovative platform and focused pipeline, Vaxcyte seeks to address critical gaps in vaccine coverage and deliver meaningful advancements in public health worldwide.
AI Generated. May Contain Errors.
Free PCVX Stock Alerts